Durable improvement in clinical outcomes in treatmentnaive patients with relapsing-remitting multiple sclerosis who switched from SC IFNB-1a to alemtuzumab (care-MS I extension study 4-year follow-up)

STUDY SUPPORT: Sanofi Genzyme and Bayer HealthCare Pharmaceuticals. CO-G: Speaking and/or consultancy (Bayer, Biogen, Merck Serono, Novartis, Roche, Sanofi Genzyme, and Teva). RA: Honoria, scientific advisory boards, and research grants (Bayer, Biogen, Biologix, Genpharm, Novartis, GSK, Lundbeck, Merck Serono, Sanofi Genzyme). DB: Compensation for advisory board participant, lecture and travel (Bayer, Biogen, Merck, Sanofi Genzyme, and Teva). ANB: Consulting fees/participated in clinical trials (Bayer HealthCare, Biogen, Merck Serono, Novartis, Sanofi Aventis, Sanofi Genzyme, and Teva Pharmaceuticals). PM: Consulting and/or speaking fees (Biogen, Novartis, Sanofi Aventis, and Teva Pharmaceuticals). BS: Consulting, speaking fees and/or grant/research support (Acorda, Biogen, EMD Serono, Mallinckrodt, Novartis, Sanofi Genzyme, and Teva). BVW: Research and travel grants, honoraria for MS expert advice and speakers fees (BayerSchering, Biogen, Merck-Serono, Novartis, Roche, Sanofi Genzyme, and Teva). DHM, KT and CER: Employees of Sanofi Genzyme. PV: Consulting and/or speaking fees, and research support (Almirall, Bayer, Biogen, GlaxoSmithKline, Merck Serono, Novartis, Sanofi Genzyme, and Teva).